Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

May 31, 2015

Conditions
Resectable Pancreatic Cancer
Interventions
DRUG

Gemcitabine and Abraxane

3 treatments for gemcitabine and abraxane every 28-days for 3 months, prior to surgery.

Trial Locations (4)

19047

University of Pittsburg Medical Center, Pittsburgh

49505

St Mary's / Trinity Health Care, Grand Rapids

55408

Virginia Piper Cancer Institute, Minneapolis

85258

TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Pancreatic Cancer Research Team

OTHER